With our proprietary GreenGlia Technology, you can target specific glia and neuron cells never before accessible. This enables revolutionary treatments for Alzheimer’s, Parkinson’s, Traumatic Brain Injury, ALS and any other central nervous system (CNS) disease.
Gene therapy for CNS conditions promises great potential cures. But so far development has been slowed by lack of ability to target and access the right cells, and limited gene expression. Now, the nVector platform can help overcome those barriers.
Identity and access the right viral capsid customized to your unique needs.
Developing treatments addressing ALS, Huntington’s and Parkinson’s and beyond.
Offering the first biologic diagnostic test for ALS.
Customized CNS biomarker testing and development.
